Multi-Gene Assay Predicts Recurrence In Newly Diagnosed Breast Cancer
FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds
Surgery Without Radiation Found Inadequate for DCIS
QOL With Femara Comparable To Placebo, Analysis Finds
EMEND Improved Emesis In Men And Women, Trials Find
Biopsies Could Be Reduced By Computer-Aided-Detection
Chemo+Radiation Preserves Voice, RTOG Study Finds
Low-Dose IFN Not Effective Against Melanoma, Study Finds
NeoPharm To Begin Phase III Trial For Glioblastoma
Elderly Men Say Physicians Are Recommending PSA Tests
NCI-Approved Protocols Listed
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
